AB
The startup develops preclinical assays for drug discovery, focusing on a drug screening platform that evaluates targeted therapies for chronic myeloid leukemia and non-small cell lung carcinoma. By identifying mutations in target oncogenes that contribute to clinical resistance, the platform accelerates the development of effective therapeutics for patients.
Updated 2 months ago
Funding
$120K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops preclinical assays for drug discovery, focusing on a drug screening platform that evaluates targeted therapies for chronic myeloid leukemia and non-small cell lung carcinoma. By identifying mutations in target oncogenes that contribute to clinical resistance, the platform accelerates the development of effective therapeutics for patients.